Basic Information
| RNALocate ID: | RLID:11003627 |
| RNA Symbol: | hsa-miR-16-2-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-16-2-3p |
| RNA ID: | miRBase:MIMAT0004518 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:11003626 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11003628 | Microvesicle | Serum | 24797360 |
| RLID-D:11000181 | Exosome | Blood|Chronic lymphocytic leukemia cells|Tongue tissue | |
| RLID-D:11000593 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-16-2-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18657 |
| MNDR | hsa-miR-16-2-3p | Lymphoma | MNDR-E-MI-18658 |
| MNDR | hsa-miR-16-2-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18659 |
| MNDR | hsa-miR-16-2-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18660 |
| MNDR | hsa-miR-16-2-3p | Prostate cancer | MNDR-E-MI-18661 |
| MNDR | hsa-miR-16-2-3p | Alzheimer disease | MNDR-E-MI-18662 |
| MNDR | hsa-miR-16-2-3p | Intracranial aneurysm | MNDR-E-MI-18663 |
| MNDR | hsa-miR-16-2-3p | Esophageal carcinoma | MNDR-E-MI-18664 |
| MNDR | hsa-miR-16-2-3p | Seizures | MNDR-E-MI-18665 |
| MNDR | hsa-miR-16-2-3p | Leukemia | MNDR-E-MI-18666 |
| MNDR | hsa-miR-16-2-3p | Huntington disease | MNDR-E-MI-18667 |
| MNDR | hsa-miR-16-2-3p | Chorea | MNDR-E-MI-18668 |
| MNDR | hsa-miR-16-2-3p | Cardiovascular disease | MNDR-E-MI-18669 |
| MNDR | hsa-miR-16-2-3p | Parkinson disease | MNDR-E-MI-18670 |
| MNDR | hsa-miR-16-2-3p | Basal-like breast cancer | MNDR-E-MI-18671 |
| MNDR | hsa-miR-16-2-3p | Thyroid cancer | MNDR-E-MI-18672 |
| MNDR | hsa-miR-16-2-3p | Pancreatic cancer | MNDR-E-MI-18673 |
| MNDR | hsa-miR-16-2-3p | Rectum adenocarcinoma | MNDR-E-MI-18674 |
| MNDR | hsa-miR-16-2-3p | Colon cancer | MNDR-E-MI-18675 |
| MNDR | hsa-miR-16-2-3p | Colon adenocarcinoma | MNDR-E-MI-18676 |
| MNDR | hsa-miR-16-2-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18677 |
| MNDR | hsa-miR-16-2-3p | Familial ovarian cancer | MNDR-E-MI-18678 |
| MNDR | hsa-miR-16-2-3p | Prostate adenocarcinoma | MNDR-E-MI-18679 |
| MNDR | hsa-miR-16-2-3p | Carcinoma ductal breast | MNDR-E-MI-18680 |
| MNDR | hsa-miR-16-2-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-18681 |
| MNDR | hsa-miR-16-2-3p | Osteosarcoma | MNDR-E-MI-18682 |
| MNDR | hsa-miR-16-2-3p | Liposarcoma | MNDR-E-MI-18683 |
| MNDR | hsa-miR-16-2-3p | Liver cancer | MNDR-E-MI-18684 |
| MNDR | hsa-miR-16-2-3p | Gastric adenocarcinoma | MNDR-E-MI-18685 |
| MNDR | hsa-miR-16-2-3p | Cervical squamous cell carcinoma | MNDR-E-MI-18686 |
| MNDR | hsa-miR-16-2-3p | Lung squamous cell carcinoma | MNDR-E-MI-18687 |
| MNDR | hsa-miR-16-2-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-18688 |
| MNDR | hsa-miR-16-2-3p | Lung adenocarcinoma | MNDR-E-MI-18689 |
| MNDR | hsa-miR-16-2-3p | Thyroid carcinoma | MNDR-E-MI-18690 |
| MNDR | hsa-miR-16-2-3p | Bladder urothelial carcinoma | MNDR-E-MI-18691 |
| MNDR | hsa-miR-16-2-3p | Pancreatic adenocarcinoma | MNDR-E-MI-18692 |
| MNDR | hsa-miR-16-2-3p | Carcinoma renal cell | MNDR-E-MI-18693 |
| MNDR | hsa-miR-16-2-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18694 |
| MNDR | hsa-miR-16-2-3p | Renal clear cell carcinoma | MNDR-E-MI-18695 |
| MNDR | hsa-miR-16-2-3p | Cholangiocarcinoma | MNDR-E-MI-18696 |
| MNDR | hsa-miR-16-2-3p | Lung small cell carcinoma | MNDR-E-MI-18697 |
| MNDR | hsa-miR-16-2-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-18698 |
| MNDR | hsa-miR-16-2-3p | Testicular germ cell cancer | MNDR-E-MI-18699 |
| MNDR | hsa-miR-16-2-3p | Breast invasive carcinoma | MNDR-E-MI-18700 |
| MNDR | hsa-miR-16-2-3p | Hepatocellular carcinoma | MNDR-E-MI-18701 |
| MNDR | hsa-miR-16-2-3p | Familiar ovarian carcinoma | MNDR-E-MI-18702 |
| MNDR | hsa-miR-16-2-3p | Rheumatoid arthritis | MNDR-E-MI-18703 |
| MNDR | hsa-miR-16-2-3p | Malignant pleural mesothelioma | MNDR-E-MI-18704 |
| MNDR | hsa-miR-16-2-3p | Chronic fatigue syndrome | MNDR-E-MI-18705 |
| MNDR | hsa-miR-16-2-3p | Hodgkin lymphoma | MNDR-E-MI-18706 |
| MNDR | hsa-miR-16-2-3p | Neuromyelitis optica | MNDR-E-MI-18707 |
| MNDR | hsa-miR-16-2-3p | Colorectal cancer | MNDR-E-MI-18708 |
| MNDR | hsa-miR-16-2-3p | Nasopharynx carcinoma | MNDR-E-MI-18709 |
| MNDR | hsa-miR-16-2-3p | Uterine cervical neoplasms | MNDR-E-MI-18710 |
| MNDR | hsa-miR-16-2-3p | Nasopharyngeal cancer | MNDR-E-MI-18711 |
| MNDR | hsa-miR-16-2-3p | Stroke lacunar | MNDR-E-MI-18712 |
| MNDR | hsa-miR-16-2-3p | Breast cancer her3+ negative | MNDR-E-MI-18713 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | RARB | Homo sapiens | RR04232971 |
TOP